Cargando…
Long‐acting glucagon‐like peptide‐1 receptor agonists have direct access to and effects on pro‐opiomelanocortin/cocaine‐ and amphetamine‐stimulated transcript neurons in the mouse hypothalamus
Liraglutide is a glucagon‐like peptide‐1 receptor (GLP‐1R) agonist marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide reduces bodyweight, and has recently also been approved for the obesity indication. Acutely, GLP‐1 markedly reduces gastric emptying, and this...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854506/ https://www.ncbi.nlm.nih.gov/pubmed/27186357 http://dx.doi.org/10.1111/jdi.12463 |